Salarius Pharmaceuticals Rebrands as Decoy Therapeutics, Pivots to AI-Driven Antiviral Platform
核心洞察
Salarius Pharmaceuticals (搜索) will rebrand as Decoy Therapeutics (搜索) Inc. with new NASDAQ ticker "DCOY" effective January 2026, marking a strategic transformation into a platform-driven biotechnology company.
The company is advancing a proprietary peptide-conjugate platform targeting pan-coronavirus (搜索) activity and multi-viral threats including influenza (搜索) and RSV (搜索), with lead programs attracting interest from BARDA (搜索).
Decoy leverages AI and machine learning tools alongside high-speed synthesis techniques to rapidly design peptide conjugate drug candidates for respiratory viruses and gastrointestinal cancers.
Salarius Pharmaceuticals (搜索) announced its transformation into Decoy Therapeutics (搜索) Inc., with the corporate name change and new NASDAQ ticker symbol "DCOY" taking effect in early January 2026. The rebrand follows the company's recent combination with Decoy Therapeutics Inc. and represents a strategic pivot toward novel peptide-conjugate therapeutics targeting viral diseases and oncology.
"This planned rebrand reflects far more than a name change, it represents the strategic foundation of the combined companies," said Rick Pierce, Chief Executive Officer of Decoy Therapeutics (搜索). "With the merger complete, we are now singularly focused on advancing integration of Decoy's differentiated therapeutic platforms, expanding our pipeline and creating multiple value-inflection opportunities through data generation, program advancements, including getting our lead program into human clinical trials."
AI-Powered Antiviral Platform
Decoy Therapeutics (搜索) is advancing a proprietary peptide-conjugate platform designed to selectively intercept and neutralize high-value biological targets. The company's early programs address pan-coronavirus (搜索) activity and multi-viral threats, including influenza (搜索) and respiratory syncytial virus (RSV (搜索)). The lead antiviral program has attracted strategic interest from the Biomedical Advanced Research and Development Authority (BARDA (搜索)) and global health organizations, positioning the company to pursue additional non-dilutive grant funding and development partnerships.
The preclinical-stage biotechnology company leverages machine learning and artificial intelligence tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates targeting serious unmet medical needs. The company's initial pipeline focuses on respiratory viruses and gastrointestinal cancers.
Expanding Discovery Programs
Decoy is advancing next-generation discovery programs that include multi-virus decoy candidates designed to address overlapping respiratory threats and cell-based and organoid-level validation of novel GPCR (搜索) targeted drug candidates outside of antivirals. These efforts are intended to support multiple investigational new drug (IND) applications and their enabling activities, peer-reviewed publications, and partnering discussions while maintaining capital efficiency and flexibility.
The company has attracted financing from institutional investors as well as significant non-dilutive capital from the Massachusetts Life Sciences Seed Fund, the Google AI startup program and the NVIDIA Inception program. Decoy has also received QuickFire Challenge award funding provided by BARDA (搜索) through BLUE KNIGHT, a collaboration between Johnson & Johnson Innovation – JLABS and BARDA within the Administration for Strategic Preparedness and Response.
2026 Strategic Roadmap
The company's 2026 priorities include advancing lead antiviral programs toward regulatory readiness, expanding discovery and preclinical validation across multiple platforms, and leveraging AI-enabled computational infrastructure to accelerate candidate selection. Decoy also plans to pursue strategic collaborations with big pharma, technology leaders, and academic institutions while strengthening its capital structure and investor visibility.
The execution-focused approach is designed to position Decoy Therapeutics (搜索) to generate multiple development opportunities while retaining upside through partnerships and non-dilutive funding sources. The company will continue trading under the existing symbol SLRX until the effective date of the change, with stockholder approval not required for the corporate name change or new ticker symbol.
Legacy Oncology Assets
Salarius maintains its clinical-stage biopharmaceutical operations with two drug candidates for cancer patients. The company's portfolio includes seclidemstat, being studied in an investigator-initiated Phase 1/2 clinical study in hematologic cancers at MD Anderson Cancer Center as a potential treatment for myelodysplastic syndrome (搜索) (MDS) and chronic myelomonocytic leukemia (搜索) (CMML) in patients with limited treatment options. SP-3164, the company's IND-stage second asset, is an oral small molecule protein degrader.